1. Home
  2. HOMB vs GRFS Comparison

HOMB vs GRFS Comparison

Compare HOMB & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Home BancShares Inc.

HOMB

Home BancShares Inc.

HOLD

Current Price

$28.01

Market Cap

5.3B

Sector

Finance

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.20

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOMB
GRFS
Founded
1998
1940
Country
United States
Spain
Employees
N/A
25247
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
5.5B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
HOMB
GRFS
Price
$28.01
$8.20
Analyst Decision
Hold
Hold
Analyst Count
5
2
Target Price
$32.40
$10.15
AVG Volume (30 Days)
1.2M
735.4K
Earning Date
04-15-2026
07-28-2022
Dividend Yield
2.94%
1.77%
EPS Growth
19.90
N/A
EPS
2.41
N/A
Revenue
N/A
N/A
Revenue This Year
$10.99
$4.69
Revenue Next Year
$5.14
$6.49
P/E Ratio
$11.85
$18.67
Revenue Growth
N/A
N/A
52 Week Low
$24.98
$6.85
52 Week High
$30.83
$11.14

Technical Indicators

Market Signals
Indicator
HOMB
GRFS
Relative Strength Index (RSI) 58.67 50.26
Support Level $27.68 $7.52
Resistance Level $28.74 $9.78
Average True Range (ATR) 0.51 0.21
MACD 0.27 0.09
Stochastic Oscillator 72.86 77.48

Price Performance

Historical Comparison
HOMB
GRFS

About HOMB Home BancShares Inc.

Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The company has one reportable segment: The Banking Segment.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: